Brought to you by 
Zentaris and Access Oncology in cancer treatment alliance; terminated
17 Feb 2021
Executive Summary
Degussa's Zentaris AG (endocrinology and oncology) licensed Access Oncology (cancer drugs) exclusive US, Canadian, and Mexican development and marketing rights to perifosine (KRX0401), an alkylphospholipid in Phase I clinical trials for the treatment of cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zentaris and Access Oncology in cancer treatment alliance; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice